Cerebral Oxygenation and Metabolism and Severe Head Injury in Paediatrics (COMetSHIP)
NCT ID: NCT05717647
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
50 participants
OBSERVATIONAL
2023-07-01
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Broad Validation Study of a Management Algorithm Mild Head Injury in Children
NCT02357186
Study Assessing Evaluation of the Interest of Serum S100B Protein Determination in the Management of Pediatric Mild Traumatic Brain Injury
NCT02819778
Quantifying Brain Injury on Computed Tomography in Hospitalized Children
NCT04176640
Decompressive Craniectomy for Severe Traumatic Brain Injury in Children With Refractory Intracranial Hypertension
NCT03766087
Proportion of Complications in Infants with an Isolated Skull Fracture Following Mild TC.
NCT06867770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be recruited from the Paediatric Intensive Care Unit at Addenbrooke's Hospital. The patients will have major acute brain injury requiring ventilation. Patients will be unaware of the enrolment to the study due to the nature of the brain injury and requirement of sedation. The acute phase of the study is purely observational; there is a consent waiver for acute data collection to obtain a bias free sample and ensure consecutive recruitment to be able to improve validity of the data. There is precedence of such waiver and PICUs in UK have recruited to ADAPT (Large Multinational multi-centre head injury study in children with TBI, http://www.adapttrial.org/) with consent waiver for acute phase data collection with approval from UK based ethics committee, and more recently the STARSHIP study (Studying Trends of Auto-regulation in Severe Head Injury in Paediatrics https://action.org.uk/research/improving-treatment-traumatic-brain-injuries). The investigators will ask for consent for data sharing and data use for present and future research and undertake the outcome assessments at 6 and 12 months by telephone interview. The investigators know from previous studies that families remember very little about what was told soon after the injury and are therefore not able to provide valid informed consent. The investigators will wait until the child's condition is stable and the family has had a chance to get acclimatized to hospital and the extent of the child's injuries. At a time when the child's condition has stabilized and recovery has begun, the site PI (or a designated member of the research team) will approach the family or the person with parental responsibility to seek written informed consent. In all cases as far as possible, consent will be obtained prior to hospital discharge.
Mortality at 30 days and at 12 months will be evaluated as a primary outcome measure. Functional outcomes will be evaluated at 6 and 12 months when patients are routinely seen for clinical follow--up. Outcomes will be assessed using the Pediatric Quality of Life Inventory (PedsQL) and the Glasgow Outcome Scale - Extended Pediatric Revision (GOS--E Peds) by asking the parent/guardian to complete the relevant questionnaires during the clinic appointment or to return the questionnaire by post after the appointment. Comparison between ICP, brain tissue oxygen and microdialysis results will be made by calculating median values, interquartile ranges, confidence intervals and by using non-parametric statistical hypothesis tests (Man--Whitney U/ Wilcoxon signed--rank test). It is noted that this is an observational study and data collected will not guide treatment.
Given the critical condition of the brain injured patients recruited to this study there is an expectation that a proportion of participants will die despite treatment, and that the survivors will have a range of neurological deficits, that may be highly disabling. Furthermore, adverse events (e.g. sepsis) are common in this patient group. Reflecting this, an extended period of treatment in the Paediatric Intensive Care Unit and as a ward inpatient is likely. Therefore the investigators will record and report adverse events relevant to the study procedures and any serious adverse events that are related or potentially related to the study procedures.
Study sample data will be anonymised and coded using a study identifier. Anonymised research data will be stored on computers within the Division of Neurosurgery in an encrypted password-protected format. No one outside the direct study team will have access to this data. The Principal and Lead investigators will ultimately be responsible for storing all data (electronic and paper) securely in compliance with The Data Protection Act 1998.
The study is to be carried out in conformation with the spirit and the letter of the declaration of Helsinki, and in accord with the ICH Good Clinical Practice Guidelines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paediatric patients with severe traumatic brain injury undergoing multimodality monitoring
* Patients admitted with brain injury requiring ventilation and ICP monitoring
* Age group: 3 years and 16 years (children under the age of three years are excluded as the triple bolt for multimodality monitoring is not currently used for this age group)
Observational study: neuromonitoring
collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational study: neuromonitoring
collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age group: 3 years and 16 years (children under the age of three years are excluded as the triple bolt for multimodality monitoring is not currently used for this age group)
Exclusion Criteria
* Patient unlikely to survive more than 24 hours
3 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cambridge University Hospitals NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shruti Agrawal
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shruti Agrawal
Role: PRINCIPAL_INVESTIGATOR
Shruti Agrawal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cambridge University Hospitals
Cambridge, Cambridgeshire, United Kingdom
Cambridge University Hospitals
Cambridge, Cambridgeshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A096238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.